Skip to main content
Top
Published in: Abdominal Radiology 3/2011

01-06-2011 | Invited Feature Section

Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR

Authors: Carlo Bartolozzi, Valentina Battaglia, Elena Bozzi

Published in: Abdominal Radiology | Issue 3/2011

Login to get access

Abstract

Nowadays, the diagnosis of hepatocellular carcinoma (HCC) is increasingly demanded to imaging techniques. Anyway, imaging cirrhotic patients still remains a challenging issue, since pre-neoplastic hepatocellular lesions, as dysplastic nodules (DNs), may frequently mimic small neoplasms. Differently from other imaging modalities, magnetic resonance (MR) can give an accurate evaluation of both intracellular and vascular changes occurring during the carcinogenetic pathway from dysplasia to full malignancy. Both DNs and HCC may in fact show a large variety of signal intensities, strictly reflecting nodules’ characteristics, such as lesion architecture, grading, stromal components, as well as intracellular contents. In these last years, the introduction of dedicated contrast media has increased MR diagnostic efficacy, permitting to explore both vascular as well as the pathological changes occurring in the biliary and reticuloendothelial systems during the carcinogenetic process. MR performed with tissue specific contrast agents (hepatobiliary and reticulo-endothelial) may thus give an insight on this “gray area”, in whom significant histological changes are already present without an evident nodule arterial supply. This peculiar MR prerogative permits to give predictive information about the evolution trend in a cirrhotic parenchyma and to identify patients at high risk for developing carcinoma who would benefit from well-timed treatments.
Literature
1.
go back to reference Bartolozzi C, Crocetti L, Lencioni R, et al. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530PubMedCrossRef Bartolozzi C, Crocetti L, Lencioni R, et al. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530PubMedCrossRef
2.
go back to reference MacSween RNM, Burt AD, Portmann BC, et al. (2001) Pathology of the liver, 4th edn. London: Churchill Livingstone MacSween RNM, Burt AD, Portmann BC, et al. (2001) Pathology of the liver, 4th edn. London: Churchill Livingstone
3.
go back to reference Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 225(2):459–466CrossRef Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 225(2):459–466CrossRef
4.
go back to reference Kanematsu M, et al. (2008) Magnetic resonance imaging of hepatocellular carcinoma. Oncology 75(Suppl 1):65–71PubMedCrossRef Kanematsu M, et al. (2008) Magnetic resonance imaging of hepatocellular carcinoma. Oncology 75(Suppl 1):65–71PubMedCrossRef
5.
go back to reference Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681PubMedCrossRef Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681PubMedCrossRef
6.
go back to reference Reimer P, Schneider G, Schima W, et al. (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578PubMedCrossRef Reimer P, Schneider G, Schima W, et al. (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578PubMedCrossRef
7.
go back to reference Kirchin MA, Pirovano GP, Spinazzi A, et al. (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798–809PubMedCrossRef Kirchin MA, Pirovano GP, Spinazzi A, et al. (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798–809PubMedCrossRef
8.
go back to reference Giovagnoni A, Paci E (1996) Liver III. Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am Feb 4(1):61–72 Giovagnoni A, Paci E (1996) Liver III. Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am Feb 4(1):61–72
9.
go back to reference Spinazzi A, Lorusso V, Pirovano G, et al. (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5(Suppl 1):S86–S89PubMedCrossRef Spinazzi A, Lorusso V, Pirovano G, et al. (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5(Suppl 1):S86–S89PubMedCrossRef
10.
go back to reference Hamm B, Stacks T, Muhler A, et al. (1995) Phase I Clinical Evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792PubMed Hamm B, Stacks T, Muhler A, et al. (1995) Phase I Clinical Evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792PubMed
11.
go back to reference Raman SS, Leary C, Bluemke DA, et al. (2010) Improved characterization of focal liver lesions with liver specific gadoxetic acid disodium enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 34(2):163–172PubMedCrossRef Raman SS, Leary C, Bluemke DA, et al. (2010) Improved characterization of focal liver lesions with liver specific gadoxetic acid disodium enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 34(2):163–172PubMedCrossRef
12.
go back to reference Ichicawa T, Saito K, Yoshioka N, et al. (2010) Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between magnetic resonance imaging and contrast enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45(3):133–141CrossRef Ichicawa T, Saito K, Yoshioka N, et al. (2010) Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between magnetic resonance imaging and contrast enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45(3):133–141CrossRef
13.
go back to reference Seale MK, Catalano OA, Saini S, et al. (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748PubMedCrossRef Seale MK, Catalano OA, Saini S, et al. (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748PubMedCrossRef
14.
go back to reference Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276PubMed Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276PubMed
15.
go back to reference Ito K (2006) Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 58:186–199PubMedCrossRef Ito K (2006) Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 58:186–199PubMedCrossRef
16.
go back to reference Lee JY, Kim SH, Jeon YH, et al. (2010) Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr 34(1):127–134PubMedCrossRef Lee JY, Kim SH, Jeon YH, et al. (2010) Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr 34(1):127–134PubMedCrossRef
17.
go back to reference Lavelle MT, Lee VS, Rofsky NM, et al. (2001) Dynamic contrast-enhanced three-dimensional MR imaging of liver parenchyma: source images and angiographic reconstructions to define hepatic arterial anatomy. Radiology 218(2):389–394PubMed Lavelle MT, Lee VS, Rofsky NM, et al. (2001) Dynamic contrast-enhanced three-dimensional MR imaging of liver parenchyma: source images and angiographic reconstructions to define hepatic arterial anatomy. Radiology 218(2):389–394PubMed
18.
go back to reference Mori K, Yoshioka H, Takahashi N, et al. (2005) Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole triple arterial phase imaging. AJR Am J Roentgenol 184(1):63–69PubMed Mori K, Yoshioka H, Takahashi N, et al. (2005) Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole triple arterial phase imaging. AJR Am J Roentgenol 184(1):63–69PubMed
19.
go back to reference Hussain HK, Londy FJ, Francis IR, et al. (2003) Hepatic arterial phase MR imaging with automated bolus detection three dimensional fast gradient-recalled echo sequence: comparison with test bolus method. Radiology 226:558–566PubMedCrossRef Hussain HK, Londy FJ, Francis IR, et al. (2003) Hepatic arterial phase MR imaging with automated bolus detection three dimensional fast gradient-recalled echo sequence: comparison with test bolus method. Radiology 226:558–566PubMedCrossRef
20.
go back to reference Ros PR, Freeny PC, Harms SE, et al. (1995) Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488PubMed Ros PR, Freeny PC, Harms SE, et al. (1995) Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488PubMed
21.
go back to reference Roncalli M, Roz E, Coggi G, et al. (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30(5):1174–1178PubMedCrossRef Roncalli M, Roz E, Coggi G, et al. (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30(5):1174–1178PubMedCrossRef
22.
go back to reference International Consensus Group for Hepatocellular Neoplasia (2009) The International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664CrossRef International Consensus Group for Hepatocellular Neoplasia (2009) The International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664CrossRef
23.
go back to reference Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef
24.
go back to reference Shinmura R, Matsui O, Kobayashi S, et al. (2006) Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 237(2):512–519CrossRef Shinmura R, Matsui O, Kobayashi S, et al. (2006) Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 237(2):512–519CrossRef
25.
go back to reference Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef
26.
27.
go back to reference Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef
28.
go back to reference Lim JH, Choi D, Cho SK, et al. (2001) Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220:669–676PubMedCrossRef Lim JH, Choi D, Cho SK, et al. (2001) Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220:669–676PubMedCrossRef
29.
go back to reference Chen RC, Lii JM, Chou CT, et al. (2008) T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules. J Formos Med Assoc 107(10):798–805PubMedCrossRef Chen RC, Lii JM, Chou CT, et al. (2008) T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules. J Formos Med Assoc 107(10):798–805PubMedCrossRef
30.
go back to reference Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:69–693CrossRef Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:69–693CrossRef
31.
go back to reference Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef
Metadata
Title
Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR
Authors
Carlo Bartolozzi
Valentina Battaglia
Elena Bozzi
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 3/2011
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-011-9687-z

Other articles of this Issue 3/2011

Abdominal Radiology 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.